Adenosine A₃ receptor antagonists as anti-tumor treatment in human prostate cancer: an in vitro study.

ABSTRACT: Prostate cancer (PCa) is one of the most common cancers in men, and for patients with PCa that cannot be surgically resected or treated, androgen suppression therapy often results in significant adverse effects. Recent studies have shown that A3 adenosine receptors (A₃ARs) are overexpressed in prostate cancer (PCa), and several A₃AR agonists and antagonists have been investigated as potential anticancer drugs. In this study, we investigated the potential therapeutic effects of the A₃AR antagonists AR 292 and AR 357 in human PCa cell lines. LNCaP, DU-145, and PC3 cell lines were treated with AR 292 and AR 357 compounds, and their cytotoxic effects were determined using viability assays, flow cytometry, and western blotting. Moreover, the drug transporter gen

SUBMITTER: Morelli MB 

PROVIDER: S-EPMC12226426 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature